GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion.
GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The Nuvalent lung cancer drugs are under FDA review and if they’re approved, GSK plans to launch both this year.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.